Vortex Biotech Opens New State-Of-The-Art Laboratory At Manchester Science Park

Vortex Biotech Holdings Limited has officially opened its new state‑of‑the‑art laboratory facilities at Manchester Science Park, marking a major milestone in the company’s growth and its mission to advance liquid biopsy technologies for precision oncology.

The launch event, held on 26 January 2026, brought together regional stakeholders, investors and collaborators. Andy Burnham, Mayor of Greater Manchester, attended the event and delivered remarks highlighting the importance of Vortex’s relocation and the growing momentum of the life sciences sector across the region.

Andy Burnham, Mayor of Greater Manchester, commented:
Vortex Biotech’s expansion at Manchester Science Park is fantastic news for Greater Manchester and a further vote of confidence in our life sciences sector. This investment strengthens our established life sciences cluster on the Oxford Road Corridor, where companies can access the world-class research, clinical networks and talent they need to succeed. This new site will create high-skilled, high-value jobs for people across Greater Manchester, while developing diagnostic technologies that could improve the treatment of cancer worldwide.

Advancing next‑generation cancer diagnostics
The new laboratories significantly expand Vortex’s research and development capabilities. Designed to high-specifications, the facility strengthens the company’s capacity for clinical trial support, commercial services, and ongoing innovation in non‑invasive cancer diagnostics.

Vortex’s proprietary liquid biopsy platform isolates and enriches circulating tumour cells (CTCs) and other rare biomarkers from blood samples, enabling high‑sensitivity detection, monitoring, and translational research. The Manchester facility will accelerate programmes in clinical validation, biomarker discovery, and the development of commercial diagnostic applications.

Designed for collaboration at the heart of Manchester’s innovation district
Located within Manchester Science Park, the facility places Vortex at the centre of one of the UK’s most vibrant life sciences ecosystems. Its proximity to the University of Manchester, NHS Manchester Foundation Trust, and numerous academic and industry partners supports deeper collaboration and access to world‑class clinical and translational expertise.

The new site will enable Vortex to expand its work across areas such as single‑cell analysis, biomarker development and advanced data‑driven approaches, supporting the company’s long‑term strategy to enhance the precision and impact of liquid biopsy technologies.

Nigel Brooksby, Non‑Executive Chairman at Vortex, said:
The establishment of our laboratory at Manchester Science Park is a strategic step in expanding collaborations with leading academic and clinical institutions and positions the company for growth. The Park’s proximity to world‑class expertise, clinical samples and translational infrastructure is essential for advancing liquid biopsy into clinical practice.

A strong regional welcome
Guests at the launch event heard from Vortex’s leadership team and from EMV Capital. Following the presentations, attendees toured the new laboratories, viewed technology demonstrations, and joined a reception celebrating Vortex’s formal establishment in Manchester.

Joe Manning, Managing Director at MIDAS, added:
Vortex Biotech’s decision to relocate from London to Manchester Science Park shows what Greater Manchester can offer life sciences companies looking to scale. The technology being developed will enable earlier cancer detection and create new skilled jobs across diagnostics, science, data and operations.

Supporting global progress in non‑invasive diagnostics
With its new Manchester base, Vortex is now better positioned to accelerate its commercialisation pathway and advance cutting‑edge non‑invasive diagnostic solutions aimed at improving outcomes for cancer patients worldwide.